A detailed history of Accredited Investors Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Accredited Investors Inc. holds 3,203 shares of LLY stock, worth $2.49 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
3,203
Previous 17,331 81.52%
Holding current value
$2.49 Million
Previous $15.4 Million 81.52%
% of portfolio
0.17%
Previous 0.39%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$772.14 - $960.02 $10.9 Million - $13.6 Million
-14,128 Reduced 81.52%
3,203 $2.84 Million
Q3 2024

Nov 05, 2024

BUY
$772.14 - $960.02 $10.9 Million - $13.5 Million
14,113 Added 438.56%
17,331 $15.4 Million
Q2 2024

Jul 19, 2024

SELL
$724.87 - $909.04 $26,095 - $32,725
-36 Reduced 1.11%
3,218 $2.91 Million
Q1 2024

May 14, 2024

BUY
$592.2 - $792.28 $99,489 - $133,103
168 Added 5.44%
3,254 $2.53 Million
Q4 2023

Feb 07, 2024

SELL
$525.19 - $619.13 $10,503 - $12,382
-20 Reduced 0.64%
3,086 $1.8 Million
Q3 2023

Nov 07, 2023

BUY
$434.7 - $599.3 $1.35 Million - $1.86 Million
3,106 New
3,106 $1.67 Million
Q1 2023

Apr 24, 2023

BUY
$310.63 - $364.82 $1,553 - $1,824
5 Added 0.17%
2,999 $1.03 Million
Q4 2022

Feb 07, 2023

SELL
$321.55 - $374.67 $8,681 - $10,116
-27 Reduced 0.89%
2,994 $1.1 Million
Q3 2022

Nov 08, 2022

BUY
$296.48 - $337.87 $24,904 - $28,381
84 Added 2.86%
3,021 $977,000
Q2 2022

Jul 21, 2022

SELL
$278.73 - $327.27 $2,229 - $2,618
-8 Reduced 0.27%
2,937 $952,000
Q1 2022

May 06, 2022

BUY
$234.69 - $291.66 $1,877 - $2,333
8 Added 0.27%
2,945 $843,000
Q4 2021

Jan 31, 2022

SELL
$224.85 - $279.04 $31,703 - $39,344
-141 Reduced 4.58%
2,937 $811,000
Q3 2021

Nov 12, 2021

BUY
$221.6 - $272.71 $23,268 - $28,634
105 Added 3.53%
3,078 $711,000
Q2 2021

Jul 30, 2021

BUY
$180.55 - $233.54 $1,444 - $1,868
8 Added 0.27%
2,973 $682,000
Q1 2021

Apr 16, 2021

SELL
$164.32 - $212.72 $35,328 - $45,734
-215 Reduced 6.76%
2,965 $554,000
Q4 2020

Feb 11, 2021

BUY
$130.46 - $172.63 $19,047 - $25,203
146 Added 4.81%
3,180 $537,000
Q3 2020

Nov 05, 2020

SELL
$146.22 - $169.13 $731 - $845
-5 Reduced 0.16%
3,034 $449,000
Q2 2020

Jul 29, 2020

BUY
$136.42 - $164.18 $954 - $1,149
7 Added 0.23%
3,039 $499,000
Q1 2020

May 15, 2020

BUY
$119.05 - $147.35 $952 - $1,178
8 Added 0.26%
3,032 $421,000
Q4 2019

Jan 23, 2020

SELL
$106.92 - $132.43 $17,748 - $21,983
-166 Reduced 5.2%
3,024 $397,000
Q3 2019

Nov 14, 2019

BUY
$106.79 - $116.16 $7,795 - $8,479
73 Added 2.34%
3,190 $357,000
Q2 2019

Aug 13, 2019

BUY
$110.79 - $129.32 $22,601 - $26,381
204 Added 7.0%
3,117 $0
Q1 2019

Apr 17, 2019

BUY
$111.31 - $131.02 $7,680 - $9,040
69 Added 2.43%
2,913 $378,000
Q4 2018

Feb 13, 2019

SELL
$105.9 - $118.64 $12,496 - $13,999
-118 Reduced 3.98%
2,844 $329,000
Q3 2018

Oct 23, 2018

BUY
$85.86 - $107.31 $858 - $1,073
10 Added 0.34%
2,962 $318,000
Q2 2018

Jul 31, 2018

BUY
$75.7 - $86.88 $8,856 - $10,164
117 Added 4.13%
2,952 $252,000
Q1 2018

Apr 18, 2018

BUY
$74.21 - $87.6 $1,484 - $1,752
20 Added 0.71%
2,835 $219,000
Q4 2017

Jan 17, 2018

SELL
$81.94 - $87.89 $10,406 - $11,162
-127 Reduced 4.32%
2,815 $238,000
Q3 2017

Oct 30, 2017

BUY
$77.07 - $85.54 $226,739 - $251,658
2,942
2,942 $252,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $740B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Accredited Investors Inc. Portfolio

Follow Accredited Investors Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Accredited Investors Inc., based on Form 13F filings with the SEC.

News

Stay updated on Accredited Investors Inc. with notifications on news.